Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
521 AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies
Compose a Response to This Article
Other responses
No responses have been published for this article.